317P A phase II clinical study of neoadjuvant immunogenic radiotherapy followed by ivonescimab (PD-1/VEGF-A bispecific antibody) and chemotherapy in stage II-III non-small cell lung cancer

In recent years, neoadjuvant immunotherapy combined with chemotherapy has been increasingly applied in resectable non-small cell lung cancer (NSCLC). An improved pathological response correlates with survival benefit. This study is to evaluate the efficacy and safety of combining immunomodulatory radiotherapy with ivonescimab and chemotherapy in stage II–III NSCLC.